All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Skye Bioscience, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 4.1 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Evolv Technologies
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Skye Bioscience, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 4.1 for the same window. The 5 average consequence score is below the beat benchmark of 6 in the same window. We currently track 1 Healthcare story that mention Evolv Technologies, all published on March 9, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Evolv Technologies. Shared-story counts are live from our verified record — not editorial picks.
Evolv Technologies and Skye Bioscience are set to report Q4 2025 results, highlighting two critical growth vectors in the healthcare ecosystem: AI-driven physical security and metabolic clinical innovation. While Evolv faces a pivotal moment in hospital infrastructure adoption, Skye’s update will be scrutinized for progress in the competitive obesity therapeutics market.